Article
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).
The oncologist - 6 Feb 2025
Saldanha Erick F, Cordeiro de Lima Vladmir C, Fares Aline, Corassa Marcelo, Gil-Santana Leonardo, Arrieta Oscar, Soler Joao, Chamorro Diego F, Rodrigues July, Carioca Freitas Helano, Rojas Leonardo, Zuluaga Jairo, Cardona Andres F
Abstract excerpt
INTRODUCTION: ERBB2-mutant non-small cell lung cancer (NSCLC) represents approximately 1%-4% of all lung adenocarcinomas (LUADs) and has emerged as a distinct molecular subtype. Little is known about NSCLC harboring ERBB2 mutations in Latin America. This study aimed to characterize the real-world clinical characteristics and outcomes of ERBB2-mutant NSCLC in Latin America. MATERIALS AND METHODS: Patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.